Pakistani Female With Delusional Thought Processes

Assignment: Assessing and Treating Clients With Psychosis and Schizophrenia
Psychosis and schizophrenia greatly impact the brain’s normal processes, which interferes with the ability to think clearly. When symptoms of these disorders are uncontrolled, clients may struggle to function in daily life. However, clients often thrive when properly diagnosed and treated under the close supervision of a psychiatric mental health practitioner. For this Assignment, as you examine the client case study in this week’s Learning Resources, consider how you might assess and treat clients presenting with psychosis and schizophrenia.
Learning Objectives
Students will:
• Assess client factors and history to develop personalized plans of antipsychotic therapy for clients
• Analyze factors that influence pharmacokinetic and pharmacodynamic processes in clients requiring antipsychotic therapy
• Evaluate efficacy of treatment plans
• Analyze ethical and legal implications related to prescribing antipsychotic therapy to clients across the lifespan
To prepare for this Assignment:
The Assignment
Examine Case Study: Pakistani Woman with Delusional Thought Processes. (Decisions have already been made. See decision results in the attached case study)
You will be asked to make three decisions concerning the medication to prescribe to this client. Be sure to consider factors that might impact the client’s pharmacokinetic and pharmacodynamic processes.
I want you to answer the questions given to you (decision points one, two, and three) before you click on the option. The answers will be based on your decisions made and patient outcomes during the decision tree. I am looking for an essay that is long enough to cover the topic BUT short enough to keep my interest. I do not need you to tell me the treatment options available to you – I am very familiar with the cases. Remember this is a Pharmacology class that incorporates Pharmacotherapy and not a class on diagnosing disease. I want you to tell me why you selected an option (why is it the best option- using clinically relevant and patient specific data) AND why you did not choose the other options (with clinically relevant and patient specific data).
At each decision point stop to complete the following:
* Decision #1
Select what the PMHNP should do next:
• You decided to start patient on Invega Sustenna (Paliperidone) 234 mg IM followed by 156 mg IM on day 4 and monthly thereafter. (see attachment for result of decision#1)
• Why did you select this decision? Support your response with evidence and references to the Learning Resources.
• Why did you not choose Zyprexa (Olanzapine) 10 mg by mouth at bed time, or Ability (Aripiprazole) 10 mg by mouth at bed time?
• What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.
• Explain any difference between what you expected to achieve with Decision #1 and the results of the decision. Why were they different?
Decision #2
Select what the PMHNP should do next:
• You decide to continue with the same drug as in decision one but from now on to be injected in the deltoid.(see attachment for result of decision#2)
• Why did you select this decision? Support your response with evidence and references to the Learning Resources.
• Why did you not choose the options to either Invega Sustenna and start Haldol Decanoate 50 mg IM every two weeks with oral Haldol 5 mg BID or to continue Invega Sustenna IM in to the deltoid and add Abilify Maintena 300 mg intramuscular monthly plus Abilify 10 mg PO in the morning for two weeks
• What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.
• Explain any difference between what you expected to achieve with Decision #2 and the results of the decision. Why were they different?
Decision #3
Select what the PMHNP should do next:
• You decide to continue with 156mg IM in the deltoid monthly in line with decision #1 and reassess in 4 weeks (see attachment for result of decision#3)
• Why did you select this decision? Support your response with evidence and references to the Learning Resources.
• Why did you not choose the options to either Invega Sustenna and start Abilify Maintenna 400 mg IM monthly with overlapping oral Abilify 10 mg in the morning or Continuing Invega Sustenna and add -on Qsymia for weight loss.
• What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.
• Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different?
Also include how ethical considerations might impact your treatment plan and communication with clients.
Learning Resources
Required Readings

Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). New York, NY: Cambridge University Press.

Note: To access the following chapters, click on the Essential Psychopharmacology, 4th ed tab on the Stahl Online website and select the appropriate chapter. Be sure to read all sections on the left navigation bar for each chapter.
• Chapter 6, “Mood Disorders”
Stahl, S. M. (2014b). The prescriber’s guide (5th ed.). New York, NY: Cambridge University Press.

Note: To access the following medications, click on the The Prescriber\’s Guide, 5th ed tab on the Stahl Online website and select the appropriate medication.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
Note: Retrieved from Walden Library databases.

[checkout]

"Do you have an upcoming essay or assignment due?


If yes Order Similar Paper